AXL as a therapeutic target in STK11 mutant NSCLC

被引：0
|
作者：
Blo, Magnus
Rayford, Austin
Madeleine, Noelly
Gartner, Fabian
Bohan, Dana
Ruggio, Natalie
Li, Huiyu
Girard, Luc
Brekken, Rolf
Minna, John
Anerud, Marianne
Maury, Wendy
Gorcea-Carson, Claudia
Gausdal, Gro
Micklem, David R.
McCracken, Nigel
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3245
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3245
引用
收藏
页数：3
相关论文
共 50 条
  • [21] TRANSLATIONAL ENDPOINTS ASSOCIATED WITH STK11 MUTATIONS IN PATIENTS WITH NON-SQUAMOUS NSCLC
    Wu, Song
    Standifer, Nathan
    de los Reyes, Melissa
    Oberst, Micheal
    Raja, Rajv
    Barrett, Carl
    Ascierto, Maria
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A168 - A168
  • [22] STK11 mutated cervical carcinoma
    Gatalica, Zoran
    Bui, Kara
    Swensen, Jeffrey
    Xiu, Joanne
    Leary, Alexandra
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 94 - 94
  • [23] AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
    Li, Huiyu
    Liu, Zhida
    Liu, Longchao
    Zhang, Hongyi
    Han, Chuanhui
    Girard, Luc
    Park, Hyunsil
    Zhang, Anli
    Dong, Chunbo
    Ye, Jianfeng
    Rayford, Austin
    Peyton, Michael
    Li, Xiaoguang
    Avila, Kimberley
    Cao, Xuezhi
    Hu, Shuiqing
    Alam, Md Maksudul
    Akbay, Esra A.
    Solis, Luisa M.
    Behrens, Carmen
    Hernandez-Ruiz, Sharia
    Lu, Wei
    Wistuba, Ignacio
    Heymach, John, V
    Chisamore, Michael
    Micklem, David
    Gabra, Hani
    Gausdal, Gro
    Lorens, James B.
    Li, Bo
    Fu, Yang-Xin
    Minna, John D.
    Brekken, Rolf A.
    CELL REPORTS MEDICINE, 2022, 3 (03)
  • [24] XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
    Li, Xuanzong
    Zou, Bing
    Wang, Shijiang
    Wang, Linlin
    Yu, Jinming
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [25] XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
    Xuanzong Li
    Bing Zou
    Shijiang Wang
    Linlin Wang
    Jinming Yu
    Journal of Translational Medicine, 19
  • [26] STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications
    Krishnamurthy, Nithya
    Goodman, Aaron M.
    Barkauskas, Donald A.
    Kurzrock, Razelle
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 215 - 229
  • [27] STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
    Shire, Norah J.
    Klein, Alyssa B.
    Golozar, Asieh
    Collins, Jenna M.
    Fraeman, Kathy H.
    Nordstrom, Beth L.
    McEwen, Robert
    Hembrough, Todd
    Rizvi, Naiyer A.
    PLOS ONE, 2020, 15 (09):
  • [28] Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC
    Shiller, Michelle
    Johnson, Melissa
    Auber, Robert
    Patel, Sandip Pravin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [29] Somatic STK11 and Concomitant STK11/KRAS Mutational Frequency in Stage IV Lung Adenocarcinoma Adrenal Metastases
    Gleeson, Ferga C.
    Kipp, Benjamin R.
    Levy, Michael J.
    Voss, Jesse S.
    Campion, Michael B.
    Minot, Douglas M.
    Tu, Zheng J.
    Klee, Eric W.
    Lazaridis, Konstantinos N.
    Kerr, Sarah E.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) : 531 - 534
  • [30] Association of cachexia with loss of function mutations in STK11/LKB1 for NSCLC.
    Infante, Rodney E.
    Ahn, Chul
    Minna, John D.
    Iyengar, Puneeth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345